



Pulmonary Arterial Hypertension Trials

We are still recruiting patients for Pulmonary Arterial Hypertension (PAH) trials:

- (1) Bosentan for patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH), unsuitable for or post-thromboendarterectomy. Functional class II-IV.
- (2) Sildenafil and bosentan combination therapy in the treatment of patients with PAH.
- (3) Sildenafil for Left Heart Failure and secondary pulmonary hypertension.
- (4) Oral prostanoid in addition to bosentan and/or sildenafil in the treatment of patients with PAH.
- (5) Nesiritide in addition to bosentan and/or sildenafil in the treatment of patients with PAH.
- (6) Bosentan for patients with mild symptoms of pulmonary hypertension. Functional Class II. (Not candidates at present for PBS bosentan).
- (7) A selective Endothelin Receptor Antagonist (ERA), open label, for idiopathic or connective tissue related PAH.
- (8) A selective ERA for patients with CTEPH or sleep apnoea associated PAH
- (9) A novel intravenous agent in combination with other agents for PAH.
- (10) Other novel combination therapies for those who have not achieved optimal functional status on mono- or double therapy.

If you or your patients are interested, or would like further information, please contact any of the following:

Assoc Prof Anne Keogh:
E-mail: amkeogh@stvincents.com.au
Phone: 8382 2641

Dr Eugene Kotlyar:
E-mail: ekotlyar@stvincents.com.au
Phone: 8382 2641 or 0431 146 357

Research Nurses
Karen Brown:
E-mail: kmabrown@stvincents.com.au
Phone: 8382 3723

Carolyn Corrigan:
E-mail: ccorrigan@stvincents.com.au
Phone: 8382 3265

Annette Pidoux:
E-mail: apidoux@stvincents.com.au
Phone: 8382 3785